Abstract
AbstractHyperpigmentation disorders are commonly diagnosed dermatologic conditions that can be cosmetically distressing for patients and cause negative psychosocial impacts. There is a need to better understand the underlying pathophysiology of pigmentary disorders as well as develop improvements in the management of these disorders. Here, we evaluated a p300 (CBP/p300) histone acetyltransferase (HAT) inhibitor, A-485, to determine if epigenetically targeting melanogenesis could be of therapeutic value. We find that A-485 treatment of primary human melanocytes and SK-MEL-30 melanoma cells drastically reduces the mRNA and protein expression of MITF and DCT, genes involved in melanin synthesis, and that this is accompanied by a reduction in melanin content. These results suggest that epigenetically targeting melanin synthesis with the A-485 p300 HAT inhibitor may be beneficial for the treatment of hyperpigmentation disorders.
Publisher
Cold Spring Harbor Laboratory
Reference13 articles.
1. Common dermatologic disorders in skin of color: a comparative practice survey;Cutis,2007
2. Bureau, U. S. C. (2012, December 12, 2012). U.S. Census Bureau Projections Show a Slower Growing, Older, More Diverse Nation a Half Century from Now https://www.census.gov/newsroom/releases/archives/population/cb12-243.html
3. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
4. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding;Journal of Virology,1993
5. Dynamics of Melanogenesis Intermediates.